-
Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation
The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global…
-
test
document.getElementById(“video”).style.height=document.getElementById(“video”).scr
-
At ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
-
Prof. Olaf Penack: Standardized GVHD Management in Europe and Future Strategies | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note: The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of…
-
Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…
-
Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC
At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of…
-
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China, the International Workshop on Cell Therapy of Blood Diseases hosted by the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science (IHCAMS) and supported by the Ministry of…
Connecting Medical Expertise through Media